找回密码
 注册

QQ登录

只需一步,快速开始

搜索
楼主: 金融角斗士

扣动扳机了

[复制链接]
 楼主| 发表于 2013-7-10 23:48:35 | 显示全部楼层
KNDI是否复制CLNT的走势?反弹再次下跌?里面的复制逻辑是什么?无法解释,
 楼主| 发表于 2013-7-11 00:23:58 | 显示全部楼层
脉冲股:CLNT,MY,KNDI
看了他们的历史走势很类似,属于脉冲股:暴涨几天几周,然后几个月阴跌,里面的逻辑大致:
他们的共同特点
1)基本面逐渐变好或突然改变为好
2)都在底部徘徊,没有形成上升通道,我无法确定自己买入后就开始上升了,虽然基本面逐渐变好或突然改变为好
3)不像FENG,开始走向慢牛
4)也不像其他美国慢牛走势
5)我估计暴涨是国人在爆炒这些股,但是美国本地人却不看好或不跟风他们,无人响应,或者他们对这些股票不了解(的确不了解),不愿意长期投资(形成慢牛)
6)对这些股票看来暴涨就走人(指短期几天或几周20-80%),然后等几个月等价格跌到前期低点再次介入等待暴涨再走人,来回重复操作。
7)在高抛等待期间,可以在3个之间介入,看哪个先跌到位,或资金等待某个跌到位置介入
8)如果没有7)的机会,就等待FENG,NM等慢牛回调时刻或周期股;mcp,avl,SVLC( 白银)介入来观察这些脉冲股票是否跌到位置在此等待暴涨
9)如此操作比较累人,但是理想的状态至少每年100%,弄得好200-300%,最少也有30-50%的利润,和巴菲特比肩
9)介入慢牛快马(LITB)最好,最省力,那等待周期股彻底止跌向上,目标:MCP,AVL,(比较合适)SVLC(白银),这些周期股类似快速帆船,还有NM,FENG,(慢牛类)
10)比较开心好玩的操作:等暴涨走人+骑上快马或快速帆船(便骑马便观察暴涨的机会,随时再次玩暴涨)
 楼主| 发表于 2013-7-11 12:29:57 | 显示全部楼层

How U.S. Investors Got Punk'd By Kandi
Jul 10 2013, 19:49  | 35 comments  |  about: KNDI

Disclosure: I am short KNDI. (More...)

(Editors' Note: This article mentions micro-cap stocks. Please be aware of the risks associated with these stocks.)

When I last wrote about Kandi Technologies (KNDI), the stock had been sitting at roughly 50% above where it is currently. The stock has now fallen from the $7-8 range down to the $4-5 range due to subsequent events. During this time, shares of Tesla Motors (TSLA) have continued to hit new highs, recently breaking above $125. As I have stated before, Tesla and Kandi have virtually nothing in common, so this divergence should not have come as a surprise. Yet it had previously been the case that numerous articles had suggested that there should be a direct correlation between Kandi and Tesla share prices.

The purpose of this article is not to say "I told you so." Instead it is to encourage investors to further reevaluate the "facts" upon which they have been relying regarding Kandi.

My last article was long, but the key points can be summarized as follows:

    Kandi had $25 million in debt coming due during the week of June 24th -- but lacked the money to pay these debts
    In anticipation, Kandi filed an S3 registration statement in April -- but the stock lacked both the price and the volume to sell enough stock
    Just two days after the S3 was filed, a highly organized promotion campaign was begun in order to lift the price and volume
    The promotion consisted of the following:
        Aggressive articles predicting a meteoric rise in the stock
        Press placements of headlines with sites such as Motley Fool and CNN Money
        Press releases by Kandi touting minor non-events
        All of a, b and c were synced with a coordinated buying campaign, temporarily increasing both the price and volume of Kandi stock

This plan worked quite well. Kandi's stock more than doubled. Volume increased by as much as 400-fold.

As predicted, within 3 days of my article, Kandi issued $26 million in stock. The amount coincided precisely with what was needed by Kandi for debts. The date coincided perfectly with the timing of these debts. Despite these coincidences, Kandi has stated that the proceeds of this financing will only be used for "general corporate purposes."

Just two days prior to announcing the financing, Kandi put out a press release in response to my article. It basically told investors the following:

- Kandi's debts had been paid

- Kandi didn't need to raise money

- Kandi had not been selling stock under the S3

For those who were still on the fence, Kandi included a punchy last paragraph to their press release to remove all doubt that it was safe to continue buying Kandi. Kandi stated that:

    "The Company filed a similar shelf S-3 registration statement with the SEC on November 19, 2009 which became effective December 24, 2009. Almost one year after that S-3 registration statement became effective, on December 21, 2010, the Company raised approximately $16 million with a shelf take down."

This reassurance clearly worked well. Apparently Kandi didn't need any money and was unlikely to be selling stock for up to a year. The stock quickly rose back to $7.18 that Tuesday. However, on Wednesday, Kandi announced that it had already sold over $26 million in stock at $6.03 plus millions of shares in warrants. The stock quickly fell to $6.03 and then continued its descent back into the $4-5 range.

US retail investors who fell for this ruse are now likely feeling "punk'd." There were several months of promotion leading up to this moment. But the last minute reassuring press release from Kandi was clearly the crescendo.

We can see from the disclosed engagement letter that FT Global had already been signed up as a "placement agent" on the fundraising, a full week before the reassuring press release was issued by Kandi. FT Global was appointed on June 18th.

But some investors continue to search for excuses on how this farce is actually great news for Kandi.

The truth of the matter is that the "institutional" investors received so many warrants in the offering that their real effective purchase price is just $4.37. This was a no brainer trade for any institution when the stock was sitting at $6.50. Even when selling at $5.00 (or below), these investors will pocket millions with minimal risk.

If I had been given the opportunity to buy a $6.50 stock for $4.37, I would have participated in the deal and happily made a few million dollars in risk free profits as well. I would have gladly done so even though I am extremely bearish on Kandi's business prospects, because it was a "free money" trade.

This was an easy arbitrage, not an investment in Kandi.

By giving out free warrants, the company is subsidizing the purchase of the stock. As shown below, the warrants are worth around $7 million. These investors were therefore paying $26.3 million, but receiving $7 million in warrants back immediately. Their net cost on the stock is around $19 million. Therefore, the actual amount that they are paying for each share is just $4.37.

As an investment banker, I spent years demonstrating similar economics to CEOs of multi-billion dollar public companies. The full calculations are demonstrated in Appendix I, along with the assumptions used for the Black-Scholes model. They are all consistent with prices demonstrated by Kandi's current options trading.

For some reason, some small retail investors seem to think that several "institutions" are making a bullish bet on Kandi at $6.03. They also think that these warrants at $7.24 imply that Kandi is expected to actually rise to that level.

Neither is the case. Instead, this was a predatory financing.

The negative impact on other shareholders has already begun to demonstrate itself. And if history is any guide, Kandi will fall much further.

The fund that participated in the deal was a Cayman Islands based fund called Capital Ventures. Their "investment manager" is Heights Capital Management of San Francisco. We can see by looking at the past 13Gs filed by this fund that they are a financier of last resort for companies that are either in distress or are otherwise unable to raise new funding.

They specialize in engineering highly dilutive deals for "new energy" companies that appear to be in terminal condition.

Examples of past investments include the following:

- B456 Systems - Formerly A123 Systems (AONEQ.PK). Last traded for 3 cents with a market cap of $6 million. Was once a multi-billion dollar battery supplier to EV manufacturers.

- Tengion (TNGN.OB). An OTC BB company developing "artificial organs." The stock has traded down 80% to 50 cents. Market cap of $1 million.

- Wireless Ronin (RNIN). A "digital media" company with a 70 cent share price and a $4 million market cap. Stock is down 70% this year.

- Plug Power (PLUG). A 38 cent "alt energy" stock that is down 70% in the past year.

- Alamo Energy (ALME.OB). A pink sheets oil and gas stock with a price of below 1 cent.

The key point to take away from these deals is that Capital is a predatory financier that profits by getting into extremely cheap deals from companies who are desperate enough to offer them terms. Capital profits by selling these cheaply acquired stocks on the way down, not by picking winners who are about to go up. This is what explains to tremendous warrant coverage and the $4.37 effective purchase price that Kandi gave up to these investors.

Additional examples are numerous and can be found by viewing the filings.

Capital's only other Chinese investment was in China Medicine Corp. This company ended up defaulting on its debts and being delisted to the pink sheets. It subsequently conducted a voluntary withdrawal from the pink sheets and is no longer traded.

With Kandi, Capital made sure that there were enough warrants included in the deal to ensure that nothing could go wrong for their investment -- even as Kandi plunged.

In fact, there appears to be a built in incentive for the fund to sell Kandi stock sooner rather than later. In looking at the Form of Warrant document, we can see the following limitations, which would prevent the holder from exercising his warrant.

    Notwithstanding anything to the contrary contained in this Warrant, this Warrant shall not be exercisable by the Holder hereof to the extent (but only to the extent) that the Holder together with any of its affiliates would beneficially own in excess of 4.99% (the "Maximum Percentage") of the Common Stock after giving effect to such exercise.

Capital had already purchased over 5% of the outstanding share count of Kandi common stock in the offering. Obviously the easy way to ensure that the warrants can be exercised is for the fund to simply sell all of the stock that it purchased.

The point from this is that this "institution" did not invest in Kandi to take a long-term view on share price appreciation. They simply received so many shares and warrants from the trade that they were nearly guaranteed to make a substantial profit, even when selling into a falling share price.

Investors who have been on this wild ride may now be asking what was the point of "running the stock" to $8.50 if Kandi would just end up handing shares to investors for $4.37.

The point is that when the stock was at $3.70 and trading on around 60,000 shares per day, no equity financing was possible. The share price was too low and the volume was too light to issue a meaningful number of shares.

Sadly, getting the stock up to $8.50 was the only way for Kandi to get investors to buy in at a still low share price of $4.37.

Now that Kandi has this money, there remains very little incentive for the company and its promoters to continue "running the stock." This should be self evident given the share price declines that have followed the huge equity and warrant offering.

Even bigger problems for Kandi

There have been many pump articles that caused Kandi to rise dramatically over the past few weeks. However, it remains the case that the only real "news" that might have an impact on Kandi's future came solely in the form of two press releases.

On June 5th, Kandi announced the MIIT approval of the Kandi Geely sedan. The share price quickly doubled, briefly hitting $8.50.

When the share price quickly faded to around $6.00 (a 30% decline), Kandi quickly issued a second press release on June 17th, which stated that HangZhou had started construction on a charging facility that would use 5,000-10,000 Kandi cars. Kandi soared by 30% once again, hitting $8.30.

In both cases, the "news" was released weeks after the developments actually occurred. Kandi simply selected the optimal time to put out these press releases. The timing worked well in terms of raising the share price right before the equity offering.

In my last article, I already described how each of these events are (in reality) non-events for Kandi.

The MIIT approval applies to hundreds of other EV manufacturers and their models. None of them trumpeted the "news" with a press release. Even Geely's stock did not budge on the news. Yet Kandi's trumpeting (along with promotional articles) caused the stock to double (temporarily).

The HangZhou news had been announced a year earlier as 20,000 vehicles. The new news was actually a decline of as much as 75%. Yet for some reason it still caused the shares to jump to $8.30 (temporarily).

Neither of these "news events" should have resulted in a significant boost in Kandi's share price from its then level of around $3.70.

But in fact, the reality of this "news" is actually much worse.

The Geely partnership was originally announced in February, causing Kandi's stock to rise by 11%. As with the recent developments, the timing of this news also appears to have been correlated with warrant activity and Kandi's attempts to raise money. Just prior to the news, Kandi had amended a warrant purchase agreement with two investors. The warrants on over 300,000 shares were set to expire worthless on January 22nd, so Kandi voluntarily extended the term of the warrants to March. The intent was to allow warrant holders to make money while Kandi would end up issuing over 300,000 new shares and receive proceeds. The warrants had a resettable price to as low as $2.75, but would have been exercisable ultimately at around $4.00-5.00.

Although much hype has been given to the Geely partnership, it seems that no one has bothered to read the disclosure that came from Geely.

    The JV Company will be owned as to 50% by Shanghai Maple of the JV Company: Guorun and as to 50% by Kandi Vehicles.

    The JV Company will not become a subsidiary of the Group or Kandi Group and its financial results will not be consolidated into the financial statements of either the Group or Kandi Group or their respective subsidiaries.

The fact that the Geely JV Company will not be a Kandi sub and will not even consolidate the financial results has not been mentioned by Kandi or its promoters. But the financial implications for Kandi should be painfully obvious to Kandi shareholders.

In addition, this agreement still requires a capital contribution of $80 million by Kandi, which Kandi clearly does not have.

To be clear, Kandi needs Geely in order to proceed. Geely does not need Kandi. The EV that received MIIT approval was model number JL7001BEV. The "JL" stands for JiLi (吉利), which is Geely's name in Chinese. From the attachment on the MIIT website, we can see that the vehicle is registered to Geely and not to Kandi.

In fact, Kandi's other promising vehicle candidate was also not even a Kandi vehicle.

Kandi first announced the HangZhou "contract" in October of 2012. The "buyer" was China Aviation Lithium Battery (CALB, 中航锂电(杭州)有限公司), which is a subsidiary of a Sichuan Company called "ChengFei" (四川成飞集成科技股份有限公司).

The model number was quoted as JNJ6290EV. But we can once again see from the MIIT website that this model is actually owned by a different car company called Zotye (pronounced ZhongTai in Chinese, 众泰汽车). The models, which were to be supplied to the HangZhou rental project, are in fact ZhongTai models, not Kandi models.

This problem likely stems from the fact that Kandi is not even licensed in China to make Electric Vehicles for use on roads (i.e., non go carts or ATVs).

We can see from Kandi's filings with China's State Administration for Industry and Commerce ("SAIC") filings that Kandi is licensed to make the types of golf carts and go carts that are not highway legal. In Chinese these are shown on the filing as 电动车、专用车. But Kandi's license also specifically says (不含汽车), which means "does not include automobiles." 汽车 is Chinese for street legal automobiles. The filing can be found here.

This would help to explain why Kandi keeps effectively "renting" the right to make licensed vehicles from other companies such as Geely and ZhongTai, who are allowed to do so.

From the Kandi announcement regarding CALB and HangZhou, we can see that:

    Under the sales contract, the temporarily scheduled deliveries of the 5,000 vehicles will occur from September 29th to December 31st, 2012.

Yet according to its 10K filing for 2012, Kandi only sold a TOTAL of 3,915 "Super-mini cars" for the entire year of 2012. All of its other stated sales are for go carts and ATV type vehicles. It is important to note that the 3,915 total included all cars made before September 29, along with any and all cars sold pursuant to the "contract" with CALB.

The biggest problem here is that Kandi had stated that

    Zhejiang Kandi Vehicles Co., Ltd. ('Kandi Vehicles') has signed the sales contract with China Aviation Lithium Battery (Hangzhou) Co., Ltd. ('CALB Hangzhou') to provide the first 5,000 EVs

But when we look at the actual documents in Chinese (put out by ChengFei, not by Kandi) , we can see that it is in fact only a "cooperation letter of intent" (合作意向协议, subject to competitive bidding (中标) and lacks legal binding (不确定性).

This now explains why the sales never materialized. The "contract" was not a contract.

The two press releases issued in June (along with heavy promotion) caused Kandi's shares to double. Volume increased by 100-400x. This all occurred just in time for Kandi to complete a much needed (and very predictable) financing.

But with the Geely approval announcement, any results will not even end up within Kandi's financials. Shareholders will not benefit.

With the latest HangZhou news, we can see from the past that the "sales contract" was actually a not a contract at all.

Fortunately, Kandi was very quick in cashing in on the share price spike, raising $26 million in new money and allowing new investors to get in with an in price of just $4.37.

But now there is a predatory fund, which is likely putting pressure on Kandi's share price. At the same time, investors are gaining an understanding that the two "news" releases did not merit a substantial rise in the stock from its then level of around $3.70.

Based on these factors, I strongly expect the share price to return to below $4.00 and volume to quickly subside to less than 100,000 shares per day once again.

Conclusion

Those who benefit from a rise in Kandi's stock price have been quick and brutal in their criticism of my findings.

Over the years I have written many cautious articles regarding pumps, promotions and outright frauds in the US and in China. On many occasions I have received death threats and threats of lawsuits from those who wanted to see my articles pulled. I have never agreed to pull any of my articles.

Some of the more problematic companies I have highlighted include China Media Express (CHMD.PK), China Biotics (CHBT.PK), Ziopharm Oncology (ZIOP) and Uni-Pixel (UNXL).

These are just a few notable examples. There are many, many more.

Once the dust settles and people have a chance to get a clearer perspective, I often receive a small number of thank you notes and an even smaller number of apologies from my critics.

When I wrote my first article on Kandi, I made it clear that a large financing was imminent. This was simply what the facts should have led us to conclude. The financing happened just 3 days later.

I do not simply write my own musings about what I "think." I write about situations where I can demonstrate adequate basis. I continue to receive new information on Kandi from readers in China almost every day. I expect to continue sorting out these new findings and will hopefully provide one or more additional updates in the next few weeks.

Investors in Kandi should strongly consider reviewing all possible findings with a critical eye to determine the validity of the hyper-bull thesis that caused the stock to double just in time for the $26 million financing. They should also consider the negative implications of having just completed a highly dilutive and predatory warrant financing.

Now that Kandi has gotten the money it was after, there is no near-term incentive to hype the story or promote the stock. As in the past, Kandi's share price will likely fall back to below $4.00.

Appendix I - calculating the value of the free warrants

In connection with the offering of stock at $6.03 per share, Kandi offered two classes of warrants. There were 1,750,415 warrants offered with a 30 month maturity and a strike price of $7.24. There were also 728,936 warrants offered with a 60 day maturity and a strike price of $7.24.

Investors who wish to independently value these warrants can refer to the current prices and volatility numbers for Kandi's existing options which are actively traded.

(click to enlarge)
 楼主| 发表于 2013-7-11 12:30:37 | 显示全部楼层
这编文章看得我发毛,准备越过成本价就走人KNDI
 楼主| 发表于 2013-7-11 13:41:49 | 显示全部楼层
一、本期业绩预计情况

    1、业绩预告期间:2013年01月01日——2013年06月30日
    2、预计的业绩:同比上升
  项 目      本报告期     上年同期   
归属于上市公司股东的净利润     比上年同期上升10% - 20%     盈利:1,895.40万元  
盈利:2,084.94万元 –2,274.48万元   

  二、业绩预告预审计情况

    业绩预告未经注册会计师审计。

  三、业绩变动原因说明

     报告期内,公司经营业绩较去年同期较快增长,其中系统集成业务增长超过50%,IT基础设施服务也实现稳步增长;但由于公司在电信等新行业的持续市场投入和大幅增加的软件开发投入,以及价格竞争而引起毛利率的下降,影响了报告期净利润的同比例增长,但报告内归属于上市公司股东的净利润仍实现一定幅度的增长。

  报告期内,公司非经营性损益预计为2.42万元,公司预计报告期的净利润为2,084.94万元至2,274.48万元之间,因此非经营性损益对净利润的影响较小。

  本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。

  四、其他相关说明

    1、本次业绩预告数据是公司财务部门初步测算的结果,未经审计机构审计。

  2、2013年半年度业绩的具体数据将在公司2013年半年度报告中详细披露。

  敬请广大投资者谨慎决策,注意投资风险。

 楼主| 发表于 2013-7-11 13:43:03 | 显示全部楼层
KNDI有值得怀疑的地方,但是不太可能大规模造假,欺骗政府和公众仅仅获得1.几个亿元的投资
 楼主| 发表于 2013-7-11 14:28:36 | 显示全部楼层
投资建议:

  彩超是理邦仪器重点打造的产品系列,也是支撑公司未来3-5年增长的主力产品。公司新的推车式彩超U2面市并获得国内注册证,将打开国内市场的巨大替代空间,前景较为乐观。我们坚持此前的观点,在出口呈现弱复苏的背景下,新的产品系列将带动公司进入一个崭新的成长周期,预测公司13-15年EPS分别为0.48/0.70/0.99元,对应PE分别为35.2/24.3/17.2X,维持“推荐”评级。

  事件:

  公司公告6月25日其“推车式全数字彩色超声诊断系统”获得广东省食品药品监督管理局颁发《医疗器械注册证》,注册号为“粤食药监械(准)字2013第2230663号”,有效期至2017年6月20日。

  要点:

  国内彩超市场蓬勃发展,中低端彩超增势尤佳

  我国彩超市场目前有三个显著特点:1)行业规模不俗,增长快速。根据inMedica的统计,我国12年超声市场规模达6.2亿美元(同期海关数据显示12年彩超进口规模达8.6亿美元),过去5年CAGR约24%,显示了良好的成长性。2)县级以下医院装备比率较低,未来将成为增长主力。调查数据显示样本医院中二级医院平均彩超装备数2.9台,一级医院1.0台,整体仍以黑白超为主,彩超装备比率较低,未来对于黑白超的替代将是主要增长动力。3)彩超单价较高,主要供给为外企占据。12年我国进口彩超1.1万台,单价达8.02万美元,较高的单价约束了县级及以下医院的购买能力;同时,由于彩超技术要求较高,外企占据了近9成国内市场份额,进口替代空间充足。    

  U2获国内注册证,公司彩超再上一个台阶

  公司12年上半年第一款入门级便携式彩超U50面市,并在欧洲等地开始销售,短短半年时间销售突破百台。经过美国团队的不断升级,公司新的推车式彩超U2也投放市场,其在图像质量及稳定性方面均有较大幅度提升,展示了公司较强的研发与技术革新能力。理邦彩超性价比高(U50售价仅15-20万元,而高端黑白超售价也超过15万元),在国内县级以下医院市场具有竞争优势,将实现对黑白超及进口产品的双重替代;后续公司还将不断提升产品性能,预计2-3年内有望进入中高端领域,实现跨越式发展。

  维持“推荐”评级

  U50此前主要在欧洲及新兴市场销售,U2的国内获批对公司意义较大,新产品、新市场将极大提升公司彩超的成长动力。预测公司13-15年EPS分别为0.48/0.70/0.99元,对应PE分别为35.2/24.3/17.2X,维持“推荐”评级。

  风险提示:与迈瑞诉讼全面败诉风险;海外市场波动加剧风险;新产品注册进度低预期风险;小非减持风险。

 楼主| 发表于 2013-7-11 14:31:16 | 显示全部楼层
公司公告:推车式彩超获批
  公司发布公告,已于2013年6月2日获得了广东省食品药品监督管理局颁发的“推车式全数字彩色超声诊断系统”《医疗器械注册证》,有效期至2017年6月20日。公司取得该产品的国内《医疗器械注册证》将进一步提升公司在超声影像领域的市场地位。
  彩超上市加速、营收贡献可观
  公司已于2013年4月10日拿到便携式彩超的国内注册证,此次推车式彩超注册证的获批进一步丰富了公司国内彩超产品线,这两款彩超此前均已获得CE认证进行出口。预计出口及国内彩超全年收入超过3千万元。
  国内以前由于彩超需要由国家药监局进行三类器械证注册而导致报批较慢。去年注册审批由三类改为二类,彩超注册批准由国家局改为省局,报批加速。我们预计公司在美国团队的研发支持和国家政策的有利环境下,彩超产品线的获批将进一步提速,除现有定位中低端的便携式彩超、定位中端的推车式彩超外,定位中高端的彩超品种也将上市。
  POCT即将获批、技术优势领先
  公司血气和电解质的POCT产品即将取得欧美认证,国内注册证也有望于3季度取得。预计POCT的出口和国内销售分别将于8、9月份展开,今年尚处市场导入期,明年将贡献可观利润。在完善血气和电解质产品线的基础上,心脏标志物POCT产品也在研发中,明后年有望获批上市。
  公司POCT产品技术领先,无论在保存方式、使用便捷性、反应灵敏性及一致性、仪器维护等方面都具有巨大优势,上市后有望迅速打开市场。
  新品研发逐步兑现,维持“谨慎增持”评级
  预计公司2013-2015年EPS分别为0.45/0.64/0.90元,对应PE40/28/20倍。考虑公司账上现金高达10亿,总市值不到30亿元,新产品POCT和彩超上市有望推动业务加速发展,维持“谨慎增持”的评级。
 楼主| 发表于 2013-7-11 15:06:27 | 显示全部楼层
2个股票很独特,
Snap1.jpg0711.jpg
 楼主| 发表于 2013-7-11 15:08:15 | 显示全部楼层
获利15%,预计会大涨50%
Snap2.jpg0711.jpg
您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|联系我们|开放平台|免责声明|小黑屋|手机版|爱股网 ( 陕ICP备19013157号 )

GMT+8, 2025-6-20 16:58

Powered by Discuz! X3.5

© 2001-2025 Discuz! Team.

快速回复 返回顶部 返回列表